Ye J, Ma C, Hsueh EC, Eickhoff CS, Zhang Y, Varvares MA, Hoft DF, Peng G
Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoyanilide hydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome
Physicians emphasize that GLP-1 medications are not intended as cosmetic weight-loss drugs and are most effective when prescribed as part of a comprehensive treatment plan that includes improved nutrition, increased physical activity and ongoing medical supervision
You can subscribe to the show here on Apple Podcasts, or Google Podcasts, or Spotify, or any app of your choice
Novo Nordisk's Uphill Battle After Eli Lilly's strong earnings report and promising drug developments, investors will be watching Novo Nordisk carefully when it reports its own Q1 2026 earnings
they want a plan